title: Cytokines involving gp130 in signal transduction suppressed growth of a mouse hybridoma cell line and enhanced its antibody production.
abstract: Three cytokines, interleukin 6 (IL-6), leukaemia inhibitory factor (LIF), and oncostatin M (OSM), that bind to composite receptors including a common signal transducer gp130 suppressed proliferation of a mouse B-cell hybridoma cell line 2E3-O cultured in serum-free medium, while they enhanced antibody production of the cells. The specific growth rate of the cells reduced from 1.0/day for control to 0.6/day for the cultures supplemented with IL-6, LIF, or OSM at 1, 4, or 2 ng/ml, respectively. The antibody productivity increased five-fold when the cells were cultured with IL-6, LIF, or OSM at 1, 25, or 20 ng/ml, respectively. Transforming growth factor beta1(TGF-beta1) similarly suppressed growth of the cells at the concentration of 5 ng/ml, while it did not enhance the antibody production. Cell cycle analysis revealed that IL-6 induced the cells to be arrested at G1 phase of the cell cycle more intensively than TGF-beta1, indicating that IL-6 and TGF-beta1 suppressed the growth through mutually different mechanisms. As a whole, this work suggests that gp130, which is commonly involved in each receptor for IL-6, LIF, and OSM, transduces signals for suppressing proliferation and possibly for enhancing antibody production in the hybridoma cells.
authors.affiliation: Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Bunkyo-ku, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Terada
authors.forename: E
authors.initials: E
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Ueda
authors.forename: F
authors.initials: F
authors.lastname: Makishima
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D015703:Antigens, CD / Q000276:immunology*; D002453:Cell Cycle; D002455:Cell Division / Q000187:drug effects; D050822:Cytokine Receptor gp130; D004357:Drug Synergism; D016193:G1 Phase; D006131:Growth Inhibitors / Q000494:pharmacology*; D006825:Hybridomas; D015850:Interleukin-6 / Q000494:pharmacology*; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000494:pharmacology*; D008562:Membrane Glycoproteins / Q000276:immunology*; D051379:Mice; D053683:Oncostatin M; D010455:Peptides / Q000494:pharmacology*; D015398:Signal Transduction; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; D006131:Growth Inhibitors; C494200:Il6st protein, mouse; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; C507838:Lif protein, mouse; D008222:Lymphokines; D008562:Membrane Glycoproteins; C508352:Osm protein, mouse; D010455:Peptides; D016212:Transforming Growth Factor beta; D053683:Oncostatin M; D050822:Cytokine Receptor gp130